Business
Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research
The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic\n\n\nNEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) (\"HOTH\" or the \"Company\"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne. The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.\n\n \n \n \n \n \n \n\n \nThe extended research collaboration will expand the scope of investigation to further understand the therapeutic mechanism of HT-003 for treatment of acne and other inflammatory skin diseases. The research will also explore safety of HT-003 in murine models. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and HOTH Senior Scientific Advisor, will be the Principal Investigator for the research collaboration.\nMr. Robb Knie, Chief Executive Officer of Hoth, commented, \"We are very excited for the potential of HT-003 as an acne therapeutic based on the recent results generated by Dr. Jonathan Zippin and we are pleased to continue our collaboration with Weill Cornell Medicine.\" \nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne and other immunological disorders. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.\nForward Looking Statements\nThis press release includes \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advance...